Meeting
2016 Gastrointestinal Cancers Symposium
Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1 trial: A phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
Authors
Li-Tzong Chen
National Health Research Institutes, National Institute of Cancer Research, Taipei, Taiwan
Li-Tzong Chen , Jens T Siveke , Andrea Wang-Gillam , Richard Hubner , Shubham Pant , Tomislav Dragovich , Vincent M. Chung , David Z. Chang , Paul J. Ross , Prasad Cooray , Niall C. Tebbutt , Fabio A. Franke , Bruce Belanger , Navreet Dhindsa , Floris De Jong , Khalid Mamlouk , Daniel D. Von Hoff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01494506
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 425)
DOI
10.1200/jco.2016.34.4_suppl.425
Abstract #
425
Poster Bd #
L19
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.
First Author: Andrea Wang-Gillam
Poster
2016 Gastrointestinal Cancers Symposium
Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
First Author: Andrea Wang-Gillam
Poster
2015 Gastrointestinal Cancers Symposium
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
First Author: Li-Tzong Chen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized multicenter phase II/III study of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX or S-IROX in patients with metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE).
First Author: Akihiro Ohba